Aarti Pharmalabs (NSE:AARTIPHARM) Debt-to-Equity: N/A (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AARTIPHARM Aarti Pharmalabs Ltd NSE:AARTIPHARM
52 GF Score
Price ₹840.70
GF Value ₹695.21
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Aarti Pharmalabs Debt-to-Equity?

Aarti Pharmalabs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹0 Mil. Aarti Pharmalabs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹0 Mil. Aarti Pharmalabs's Total Stockholders Equity for the quarter that ended in Jun. 2026 was ₹0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Aarti Pharmalabs's Debt-to-Equity or its related term are showing as below:

NSE:AARTIPHARM' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08   Med: 0.2   Max: 0.36
Current: 0.36

During the past 6 years, the highest Debt-to-Equity Ratio of Aarti Pharmalabs was 0.36. The lowest was 0.08. And the median was 0.20.

NSE:AARTIPHARM's Debt-to-Equity is ranked worse than
57.44% of 813 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs NSE:AARTIPHARM: 0.36

Aarti Pharmalabs  (NSE:AARTIPHARM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Aarti Pharmalabs Debt-to-Equity Related Terms

Aarti Pharmalabs Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Aarti Pharmalabs's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarti Pharmalabs Debt-to-Equity Chart

Aarti Pharmalabs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Debt-to-Equity
Get a 7-Day Free Trial 0.25 0.14 0.16 0.21 0.36

Aarti Pharmalabs Quarterly Data
Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.32 N/A 0.36 N/A

NSE:AARTIPHARM vs ZTS: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Pharmalabs's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aarti Pharmalabs Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarti Pharmalabs's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Aarti Pharmalabs's Debt-to-Equity falls into.


NSE:AARTIPHARM
52GF Score
Aarti Pharmalabs Ltd NSE:AARTIPHARM
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarti Pharmalabs Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Aarti Pharmalabs's Debt to Equity Ratio for the fiscal year that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(5163.739 + 2379.874) / 21246.047
=0.36

Aarti Pharmalabs's Debt to Equity Ratio for the quarter that ended in Jun. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Aarti Pharmalabs (NSE:AARTIPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Pharmalabs stock appears to be overvalued. The current stock price of ₹840.70 is trading 20.9% above its estimated GF Value™ of ₹695.21. GuruFocus considers Aarti Pharmalabs to be Modestly Overvalued.

Key valuation signals for NSE:AARTIPHARM:

  • Debt-to-Equity: N/A
  • GF Value™: ₹695.21 vs. price of ₹840.70 (20.9% above fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the NSE:AARTIPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aarti Pharmalabs Business Description

Other Exchanges 543748:India
Address Mulund Goregaon Link Road, 204, 2nd Floor, Udyog Kshetra, Mulund West, Mumbai, MH, IND, 400080
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
52GF Score

Get the complete analysis for NSE:AARTIPHARM

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹840.70
Price
₹695.21
GF Value